Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: * What are the demographic and clinical characteristics of metastatic prostate cancer patients? * How are metastatic prostate cancer patients currently treated and how effective are these treatments? * How does the development of castration-resistance affect patient outcomes? * What is the economic burden of metastatic prostate cancer?
Age range
18 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Body Mass Index (BMI)
Timeframe: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Prostate-Specific Antigen (PSA)
Timeframe: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Alkaline Phosphatase (P-AFOS)
Timeframe: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Length of Follow-up
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With de Novo Metastasis
Timeframe: Within 2 months from index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Who Received Treatment for mCRPC and mCSPC
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Diagnosed With mCSPC Who Progressed to mCRPC
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With Orchiectomy
Timeframe: Closest record any time from index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Undergone Palliative Radiology
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With Symptomatic Skeletal-Related Event (SSRE)
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants With Osteoporosis
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Who Were on Bone Medication
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Who Were on Opioids
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Classified Per Charlson Comorbidity Index (CCI) Scores
Timeframe: Up to 5 years before the index date (index date included); retrospective available data evaluated in this study for approximately 14 months
Number of Participants Classified Per Gleason Score
Timeframe: Closest record any time from index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approx.14 months
Number of Participants Based on Tumor Node Metastasis (TNM) Classification: T
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Based on Tumor Node Metastasis (TNM) Classification: N
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Based on Tumor Node Metastasis (TNM) Classification: M
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Based on Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Timeframe: Closest record during 3 months before or after the index date; retrospective available data evaluated in this study for approximately 14 months
Number of Participants According to Treatment Per Treatment Line for mPC: mCSPC Participants
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants According to Treatment Per Treatment Line for mPC: mCRPC Participants
Timeframe: Post index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Overall Survival (OS)
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Time to Next Treatment (TTNT)
Timeframe: From initiation of current treatment line until initiation of next treatment line, death censoring event, whichever occurred first, maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Time to Disease Progression
Timeframe: From mCSPC index until mCRPC index, death or censoring event, whichever occurred first, maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Participants Per Factors Associated With Disease Progression to Castration Resistant
Timeframe: From mCSPC index until mCRPC index, death or censoring event, whichever occurred first, maximum up to 24 months; retrospective available data evaluated in this study for approximately 14 months
Annual Incidence of mPC, mCSPC and mCRPC
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Events Per Participant Year for Outpatient Clinic Contacts, Hospitalization Contacts
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx. 9 years; retrospective available data evaluated in this study for approximately 14 months
Number of Days Per Participant Year for Hospital Inpatient Days
Timeframe: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx. 9 years; retrospective available data evaluated in this study for approximately 14 months